Effects of Substance P on Nicotine-Induced Cholinergic Transmissions and Contractility in Isolated Rat Atrial Preparations by Ekeze, Tobias E.
The College at Brockport: State University of New York
Digital Commons @Brockport
Biology Master’s Theses Department of Biology
5-1987
Effects of Substance P on Nicotine-Induced
Cholinergic Transmissions and Contractility in
Isolated Rat Atrial Preparations
Tobias E. Ekeze
The College at Brockport
Follow this and additional works at: https://digitalcommons.brockport.edu/bio_theses
Part of the Biology Commons
This Thesis is brought to you for free and open access by the Department of Biology at Digital Commons @Brockport. It has been accepted for
inclusion in Biology Master’s Theses by an authorized administrator of Digital Commons @Brockport. For more information, please contact
kmyers@brockport.edu.
Repository Citation
Ekeze, Tobias E., "Effects of Substance P on Nicotine-Induced Cholinergic Transmissions and Contractility in Isolated Rat Atrial
Preparations" (1987). Biology Master’s Theses. 17.
https://digitalcommons.brockport.edu/bio_theses/17
EFFECl'S CF stJBSTAN:E P � NICOI'INE-INDUCED CHOLINERGIC TRANSMISSICNS 
ANJ, COO'RACI'ILITY IN ISCXATED RAT ATRIAL PREPARATIOOS 
A Thesis 
Presented to the Faculty of the Department of Biol,ogical Sciences 
of the State University of New York College at Brockport 
in partial Fulfillment for the Degree of 
Master of Science 
by 
Tobias E. Ekeze 
May, 1987 
THES�S DEFENSE· 
APPROVED NOT APPROVED MASTER'S'DEGREE'ADVISORY'COMMITTEE 
/ f)�t c;:;d o!3t&7 
Major Advisor Date/ 
J2�{� 0/r-t I Date 
lk-� �a����r Committee Member 
........____ 
\ � lr.7_____. :!-
Cha Sciences 
\............__ 7 
II 
fo};>�as Ekeze- wap boJ:n in Lagos, Nigeria. He received his B.S. from the 
State. dJniversj.ty of � ¥ork, College at BrockpOrt in 1985. He has 
worked as a biology technician for Ward's Natural Science 
Establishment incorporation for the past two years. He was awarded a 
teaching assistanship by the department of Biological Sciences for the 
1986-87 school year. He has since served as a laborato� instructor 
for Principles of Biology, Anat� and Physiology, and Human Biology. 
TObias Ekeze received the Sigma Xi award for excellence in research 
and achievement in Biological Sciences in 1987. He was an active 
nenber of the Biology Club at State University of New York, College at 
Brockport for 6 years. Tobias Ekeze currently resides in Rochester New 
York with his wife L.W. Ekeze. 
III 
This work is dedicated to It¥ wife, Mrs. Laureen W. Ekeze for her 
su�rt, understanding, and love through the years of my study. 
IV 
ACKNOWLEDGMENTS 
I am truly grateful to Dr. Delmont C. Smith for his guidance. 
support. and sincere encouragement throughout the course of my study. 
I wish to thank Dr. David Brannigan and Dr. Stephen W. Chan for their 
support during the period of this study. I am grateful to Mr. Larry 
Fredrickson for his friendly support and for the use of his electronic 
calculator. Finally. I am indebted to my wife. Mrs. Laureen Ekeze for 
her support throughout the preparation of this Thesis. 
v 
TABLE OF CCNrENI'S 
L ISI' OF TABLFS-------­
LISI' CF FIGURES----­
Page 
--------- VI-VIa 
VII 
VIII 
INI'R<DUcr'ICN-- ------ -------- -------- -------- --------- 1 
��;------------ ---
RESULTS 
DIOCUSSI�---------· ---­
REFEREN::ES ·-----------' ---
13 
17 
------- ---- 37 
44 
VI 
Abstract 
Sprague-Dawley rats of either sex, weighing 300 to 500g, were 
anesthetized with urethane (2-3mg/g). The hearts were rapidly removed 
and placed in a dish containing CQld Krebs-Hensl�it buffer (pH 7.2:t 
.01} and continuously oxygenated with 95% oxygen, 5% carbon dioxide. 
The atria were cleared of as much extraneous tissue as possible and 
placed in an organ bath containing Krebs-Hensleit solution which was 
maintained at 31.0� .05 C and aerated with 95% oxygen, 5% carbon 
dioxide The effects of substance P (1 X 10-5 M to 4 X 10-5 M) and 
nicotine (1 X 10-5 M to 4 X 10-5 M) on atrial contractility were 
tested by the addition of these drugs to the organ bath. Contractions 
were recorded with a desk model DMP-4B Physiograph. The expected 
biphasic response to nicotine was observed at all concentrations 
tested. Substance P produced a direct inhibitory effect on atria 
contractility. This negative inotropic response to substance P was 
significant at all concentrations tested and occurred within a few 
beats (about 3 to 5 beats) from the addition of the drug to the bath. 
The negative effect of substance P was neither blocked by 
hexamathonium chloride (a nicotinic blocker) nor by atropine sulfate 
(a muscarinic blocker). No significant chronotropic response to 
substance P was observed. A control used in order to determine whether 
the acidified medium in which substance P was dissolved had itself any 
atrial effects produced no change �n either rate or force of 
contraction. No positive inotropic response to nicotine was observed 
in the presence of substance P. It is not clear whether the negative 
effect of nicotine occurred in the presence of substance P because 
substance P itself produced an immediate inhibitory effect on atrial 
contractility. It is postulated that substance P liberated from 
pain-associated fibers in the heart might have a modifying action on 
the heart. The 
direct negative 
be elucidated. 
functional role. if any. for substance P producing a 
inotropy during episodes of cardiac pain has yet to 
However. such direct negative inotropy may be 
protective by counteracting excitability produced by catecholamines 
released from adrenals during cardiac pain episodes. 
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INI'RCDtJCl'ION 
Von Euler and Gaddum (1931) were studying the distribution of 
acetylcholine in different organs when they aiscovered that extracts 
from brain and intestines caused intestinal smooth muscle contraction 
and relaxed vascular smooth rruscle in rabbit isolated intestines. 
Shortly thereafter, they used a powder prepared from the extracts as a 
standard in a nunber of experiments. This standard preparation, which 
they called P, is now known as substance P. This term entered the 
literature in 1934 and has since persisted. 
SUbstance P. was purified to horrogeneity in 1970 (Chang and 
Leeman, 1970) and its structure was established in 1971 (Chang et al 
. ,  1971). Substance P has the following amino acid sequence: 
Arg-Pro-Lys-Pro-Gln-Gln-Phe- Phe-Gly-Leu-Met-NH and belongs to a group 
of proteins knO\m as tachykinins. The preCursors of substance P have 
been cloned and sequenced' from CDNA {Lynch and Synder, 1983). 'IWo 
different putative precursor substances, called alpha- and 
beta-preprotachyk1nins have been obtained from the eDNA. These 
precursor substances have been shown to contain the structure of 
substance P (Synder et al. , 1984) • The N-terminal region of substance 
P is not essential for activity, and several C-ter.minal fragments of 
the peptide, including the octa (4-11) , hepta (5-11), and hexa (6-11) 
fragments, are also active. Depending on the preparation being 
studied, these peptides may be as potent as the intact undecapeptide 
or even more so. (Tregear et al., 1971) 
Although substance P was originally discovered in brain and 
intestines, this undecapeptide has been shO\in to be widely distributed 
in the :marrma.lian nervous system. Small amounts of substance P have 
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also been� found in various peripheral organs of several species. 
(Nilsson and Brodin, 1977). Reinec�� an9 Forssmann (1980), using a 
peroxidase-antiperoxidase · technique, showed that substance 
P-immunoreactive nerve fibers were present in the guinea pig heart. 
The bicuspid and tricuspid valves, at the at�achrnent to the heart 
wall, have been shown to be densely supplied with substance 
P-immunoreactive fibers (Elfvin et al., 1982). other areas of the 
heart that were shown to contain sub�tance P-i.rrm.moreactivity fibers 
include: the epicardium, myocardium, endocardium and the entire 
coronary aterial system. Substance P-i.nmmoreactivity has also been 
derronstrated in the guinea-pig parasyrrpathetic ganglion, vagus nerve 
and dorsal r6ot ganglia (Reinecke et al., 1982). 
Substance P is a potent vasodilator and produces a marked 
hypotensive �ction in humans and in several animal species. The 
vasodilatation results from a direct inhibitory effect of the peptide 
on arteriolar smooth.muscle (Couture and Regoli, 1982). This action is 
mediated via specific receptors that differ from those mediating the 
actions of vasodilators. In contrast to its effects on arteriolar 
snooth rruscle, substance P stimulates contraction of venous, 
intestinal, and bronchial smooth muscle. It also causes secretion in 
the salivary glands, 
(Caranikas et al., 1982) • 
-
diuresis and natriuresis in the kidneys 
Substance P has been described as a neurotransmitter or at 
least a neurornodulator in various systems. The rrost convincing 
evidence for a �ole of substance P in neurotransmission comes from 
studies on the sensory fibers in the nervous system which convey 
noxious information (Dale et al., 1935; Hellauer and Omrath, 1948; 
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Lembeck, 1953; otsuka et al., 1972). In 1948, Hellauer and Umrath 
measured noncholiper�ic vasodilator activity in extracts of dorsal and 
ventral roots and found that considerably mote activity was present in 
the dorsal than ventral roots. They proposed that this vasodilator 
activity represented th� action of the excitatory transmitter of 
sensory fibe�s. Lerrbeck (1953) obtained similar results and, in 
addition, found that the extract caused gut contraction. These 
properties were identical to those of substance P f which had been 
extracted earlier �rom gut and brain by von Euler cu;td Gaddum (1931) 
and found to be a peptide (von Euler, 1936). Thus, Lerrbeck proposed 
that substance P might be the sensory transmitter. In 1974, Takashashi 
and others showed that the same extraxts isolated from the dorsal root 
by ,Hellauer and Umrath in 1948 had precisely the same pharmacological, 
chemical, enzymatic and i.mrmmological properties as the undec¥ptide 
isolated by Chang and Leeman (1970) from hypothalarrus and identified 
by them as substance P. Up�g a bioassay, Takahashi and otsuka ( 1975) 
found that substance P was h�ghly concentrated in the dorsa+ horn of 
the spina cord and that foll�ving dorsal root ligation or section the 
concentration of substance P in the dorsal horn and the segment of the 
dorsal root nearest the cord fell markedly, whereas the �oncentration 
in the segment nearest the cell bodies increased manyfolq. Compared to 
the changes in the dorsal horn, only a slight fall in �ubstance P was 
detected in the ventral horn horn after dorsal root section. These 
results suggest that substance P is synthesized in the cell body and 
subsequently transported to the dorsal horn of the ppinal cord. 
Interestingly, Holton (1959) had earlier shown with similar ligation 
experiments that there was transport of substance P into the 
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peripheral branch sensory neurons. 
Further supp6rt for the association of substance P with pain 
sensory fibers came from studies on the distribution of substance P in 
the trigeminal nucleus (Andersen et al. , 1977). It is generally 
accepted that the nucleus caudal is of the trigeminal nuclear corrplex 
receives nociceptive input (Dubner et a1., 1976). Immunohistochemical 
studies have revealed that the highest concentration of subtance 
P-positive fibers is located in this part of the nucleus {CUello and 
Kanazawa, 1978) and that most of this immunoreactivity disappears 
after section of the trigeminal nerve (CUello et al. , 1978). This 
association is made stronger by i.rmunohistochemistry done on the tooth 
pulp afferents, which are considered to mediate only the sensation of 
pain in humans. (Adersen· et al. , 1970) • 
The distribution of J•let-enkephalin- and substance 
P-immunoreactive neurons has ·also been studied in areas related to 
pain and analgesia (Hokfelt et al. , 1977). They shO\qed that substance 
P is present in the same or adjacent·areas and also in apopulation of 
sensory neurons. The presence of substance P-.irmunoreactive fibers in 
the the guinea-pig parasyrrpathetic ganglia, vagus nerve and dorsal 
root ganglia caused sOme investigators to suggest that substance P may 
be involved in sensory transmissions since these structures are known 
to be potential sources of sensory nerve fibers in the heart. 
capsaicin, the active ingredient of pepper, decreased 
substance P-immunoreactive material in the guinea-pig heart (Papka §. 
Jai., 1981). Since capsaicin was shown to deplete substance P from 
primary sensory neurons without affecting other types of neurons 
containing substance P, it was concluded that substance 
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P-immunoLeactive fibers in the heart were involved in senso� 
transmissions (Hokfelt et al. , 1980). It is conceivable that substance 
P is involved in pain perception because the depletion of substance P 
by capsaicin might be the result of their release from the nerves. In 
addition, the action of CaPsaicin is specific to those senso� fibers 
containing substance P. These findings suggest that substance P may be 
locally released as a response to cardiac pain. 
It has been suggested that substance P may play a role in 
autonomic transmission. Immunohistochemical studies have shown that 
fibers in several sympathetic ganglia contain substance P (Hokfelt � 
al. , 1977). The physiological studies of autonomic ganglia have 
provided pharmaoqlogical evidence that substance P may mediate some 
forms of non-cholinergic slow synaptic excitation (Chang and Leeman, 
1977; Crain and Peterson, 1980; Duffy et al. , 1982). 
Substance F.-positive terminals have been shown to be present 
in the walls of arteries and veins (Barber et al. , 1979) • This 
suggests that .substance P may play a role in regulating blood flow in 
some tissues, whereas at other sites it is secreted into the 
circulation and may function as a.hornone (Sunder �t al. , 1977). But 
the finding that endothelial cells can readily degrade substance P may 
pose a problem fot the passage of substance P into circulation 
(Johnson and Erdos, 1977). 
The evidence of substance P as neuromodulator has been 
documented in many substance P systems. In some these systems, 
substance P was shown to be synthesized within the bodies of neurons 
and then transported axonally to nerve terminals where it is released 
into a synapse by an appropriate stirculation. Although substance P was 
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shown to be released into a synapse, it did not interact with the 
postsynaptic receptors on the these systems. Instead, it interacted 
with other receptors which led to a change in responsiveness of the 
postsynaptic menbrane. This kind of action was referred to as synaptic 
modulation and was first discribed by Krivoy and others in 1961. In 
their paper, a synaptic modulator was described as n a substance that 
alters· (increases or decreases) the efficiency of the transmission 
process without �r se producing a propagated response. n The 
modulato� actions of substance P has been shown in amphibia in which 
tfie substance modulated the sensitivity of the nicotinic receptors 
during cholinergic transmission (Akasu ,et al., 1983). Also, the 
inhibito� influence of substance P on nicotinic-induced response was 
observed in preparations such as 'bovine adrenal chromaffin cells 
(Livett et al. , 1979) and cat Renshaw cells (Belcher et al. , 1979). 
The prcise site and mechanism of action of substance P in these 
systems remains to t>e detennined. It was suggested by Belcher and 
Ryall (1977) that sul:5stance P may prevent charmel opening, block open 
channels, or pibhote chann�l closing. Clapham and Neher (1983) 
concluded that substance .p ·inhibits .ACH-iriluced depolarization of 
chromaffin cells either � increasing the rate of desensitization or 
� inducing charmel blockade, which indirectly enhances 
desensitization. In contrast to som: experiments that showed substance 
P to have only postsynaptic activity at cholinergic synapse, the 
action of this peptide at the frog neuromuscular junction �ared to 
be primarily presynaptic (Steinacker et al. , 1977). Some experi.nental 
findings have shown that substance P did not modulate cholinergic 
reS;PQnse by interfering with channel activation or with ion permeation 
page 7 
(Clapham et a}., 1983; Akusa et al. , 1983; Krivoy et al., 1979). Some 
of thes� authors suggested that substance P may interrupt channel 
activities by prOIWting "a transition to a transiently silent state. " 
However, · it was not distinguished whether this sil�t state was a 
blocked state" in the sense of local anaesthetic block or whether it 
was an allosteric stabilization of a desensitized state which was also 
shown to be present in the absence of substance P. 
A biphasic in vitro contractile respopse (i. e. , initial 
depression followed by a longer lasting excitation) to nicotine has 
been repc;>rted for atria from various rnamnalian species (Kottegoda, 
1953; Leaders and �ng, 1962; Trendelenberg, 1960). The fibers of the 
vagus nerve that go the heart are preganglionic fibers. They terminate 
around ganglia in the atria of the heart. Originating from these 
ganglia are short fibers that are postganglionic. These postganglionic 
fibers terminate at the effector. Acetylcholine is the 
neurotransmitter at the terro:i:nations of both neurons. Nicotine is 
specific for those receptors located on the postganglionic neurons. 
These rec�ptors are known as nicotinic receptors aqd they can be 
blocked by hexamathonium chloride. Those receptors located on effector 
are knO\-m as muscarinic receptors because they can be activated by the 
drug nuscarine. These receptors can be blocked by atropine. 
Activation of nicotinic receptors produces action potentials 
in the neurons with release of acetylcholine at the neuroeffector 
cleft and subsequent inhibition of the cardiac effector fibers by way 
of nuscar inic receptors. It has been shown that intrinsic cardiac 
nerves (ICN) are activated by nicotine which results in negative 
inotropy (Priola et al., 1977; Smith et al. , 1985). These results were 
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obtained from animals that were subjected to extrinsic cardiac 
denervation, a procedure that eliminates postganglionic �athetic 
neurons but by parasympathetic postganglionic neurons. 
Dixon (1924) reported that in the absence of atropine, the 
inhibitory effect of nicotine is followed by a stimulant action. Smith 
et al suggested that the positive component of nicotine response may 
be due to nicotine-induced catecholamine release because it was absent 
in animals that were subjected to total extrinsic cardiac denervation. 
It has been suggested that nicotinic agonists release nor�inephrine 
in sympathetically innervated tissues by initiating action potentials 
in the terminai axons. This claim is based on the evidence that during 
exposure of sympathetically innervated tissues to nicotinic agonists, 
antidromic impulses' have been detect� in ·�thetic nerve'trunks 
(Cabrera et al., 1966; Davey et al,;, 1968; Krauss .et al • , 1970; 'Bevan 
and Haeusler, 1975). It was suggested that these impulses reaching 
adrenergic nerve terminals caused release of norepin�rine (Ferry, 
1963). This proposal was tested by using tetrodotoxin (TI'X), which 
selectively bl�cks' neurona! conduction (Gershon, 1967; Davey, 1968; 
� 
Krauss, 1970). These experiments have yielded conflicting results. 
Some workers reported that tetrodotoxin blocks the response of 
isolated tissues to nicotine (Bell, 1968; Endoh et al., 1970), whereas 
others did not observe a blocking action (Su and Bevan, 1970; Westfall 
and Brasted, 1972). 
The positive inotropic effect of nicotine has been observed in 
various mantnalian heart preparations. It has been shown that nicotine 
increased the contractile force of mammalian ventricle studied in situ 
(Puri et al., 1968} and in yitro (Lee and Shideman, 1959). A large 
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proportion of this positive inotropic effect of nicotine was shown to 
have resulted indirectly from the release of endogenous catecholamines 
(Mjos and I'lebekk, 1973; Loffelholz, 1970; Toda and Hayashi, 1982). 
Koley and others (1984) reported a positive inotropism that resulted 
solely from the direct stimulation of the heart by nicotine. However, 
transient. negative and positive inotropic responses that were 
sensitive to varying degrees of antagonism by propranolol, 
hexrnathonium chloride, or atropine sulfate ·nave been· reported by many 
investigators. For exanple, Basset and others (1973) shO\'f'ed that 
nicotine {3. 1 X 10-5 to 6.2 X 10-5 Z.I) released endogenous cardiac 
catecholamine which then·transiently increased cardiac contractility. 
They also showed that the transient negative ionotropic effect. Some 
investigators reported that the positive inotropic respOnse elicited 
in the heart by nicotine may be related to the calcium metabolism of 
the T.rtocardium. For instant:e, Nayler (1963) showed that nicotine 
activated the contractile mechanism in toad ventricular muscle by 
rrobilizing calcium. Using radiolabelled calcium, Nayler was able to 
sh0\·1 that cellular calcium influx and efflux were stinulated by 
nicotine • Shine (1973} reported that the increase in the pemeability 
of the sarcolemma to calcium in rabbit ventricle was due entirely to 
the release of endogenous catecholamines because reserpinization and 
propranolol administration abolished nicotine-elicited changes in 
sarcolemmal calcium rrovernents. 
The study by Fenton and Dobson, Jr. (1985) supports some of 
the earlier findings of the cardiac action of nicotine. '!hey showed 
that endogenous catecholamine elicited by nicotine was responsible for 
the transient elevation in contractile force, and that the transient 
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contJ;actile response to nicotine was over within 45 seconds and could 
be inhibited by propranolol. Thy also reported that the beta 
adr�ergic-induced <effect of nicotine was terminated after one minute 
since propranolol had effect on the increase in the contractile force 
obervee at 1 and 2 rnin�tes with picotine infusion. In addition, they 
sh9wed �at the mJscarinic blocking agent, atrorine, had no effect on 
the contractile fqrce in the presence of progranplol, 
Nico�ine has been reported to increas� reyocardial oxygen 
consurrptio11 (Cryst� et al., 1981) • Some invest�gators reported that 
t.pe increase in reyocardial o�gen consumption was due to the indirect 
stiiTn.llation of the heart metabplisrn by catecholaminep (Berne et al. , 
.. 
1983). Adenosine has been shown 1:o roodulate contractility in the .�eart 
(�lardinelli et al. , 1983) • Itp a9tion was sho\'m to, include �hanges 
in the reyocardial oxygen cons'lJ.I'rl?tion of the heart, the responsiveness 
of the myocardium to beta-adrenergic stimulation and the velocity of 
ac�ion potentials passing through the atrio-ventricular node. Fenton 
and others (1985) showed that oxygen consunption of the heart and 
adenosine levels were elevated during the plateau of contractile force 
prod4ced by nicotine. They suggested that adenosine may influence the 
final expr�ssion of nicotine's mechanical and b).ochemical 
manifestations since a number of variables (contractility, reyocardial 
oxygen consumption and electrical activity) pt�ect� by the 
administration of nicotine also are modulated by adenosine. 
Nicotine and muscarinic receptors are subtypes of 
cholinoceptors since acetylcholine is the physiologic transmitter 
substance at both receptors. Drugs that mimic acetylcholine tend to 
sti.nulate these receptors and as such are referred to as cholinoceptor 
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stimulants. Ololinoceptor stimulants have been shown to decrease the 
slow inward calcium current in atrial and nodal cells in many species 
(Richelson and Fakahany, 1981; Yrunamura and Snyder, 1974}. In 
addition, these cholinomimetic drugs are known to cause an increase in 
membrane potassium permeabil1ty in atrial muscle cells, 
atrioventricular and sinoatrial nodes. These actions are responsible 
for the decrease of pacemaker' activities', hyperpolarization, and 
decreased contractility of atrial cells. Some cholinarnemitic alkloids 
and synthetic analogs include muscarine, nicotine, pilocarpine, 
lobeline, oxotrenorine, and dimethylphenylpiperazinium (DMPP} • 
As discussed earlier, substance P has beem used· to modulate 
cholinergic transmissions in preparations such as� Devine adrenal 
chromaffin cells (Livet et al., 1979} and cat Renshaw cells (Belcher., 
1979). In addition, the modulatory action of substance P has been 
demonstrated in various substance P systems in different species 
(Akusa et al., 1983; Krivoy ..et al . ,  1961; Clapham et al., 1983}. No 
modulatory action of substance P in the heart has been studied so far. 
However, an unpublished results obtained from in vivo experiments on 
canine heart by Smith have suggested that substance P might have a 
modifying action on autonomic neurons innervation the heart. The 
evidence for this is that during stimulation of parasympathetic 
neurons innervating the heart, reduced inhibition of cardiac 
contractibilty was observed in the presence of substance P. Also, 
stimulation of the sympathetic neurons produced a lesser increase in 
cardiac contractility in the presence of substance P. 
This present study was undertaken to determine possible 
cardiac effects of substance P Which might occur concurrently with 
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pain-producing cardiac episodes. It is postulated that substance P 
librated from pain- associated fibers in the heart might have a 
modifying action oh the heart, either directly or � modulation of 
autonomic neuron activity. It is unclear at present whether such 
modification of cardiac activity might be of a protective nature or 
whether it contributes to cardiac pathology duEing such episodes. In 
this- �riment, nicotine was used to produce cholinergic 
transmissions because the Irodulatory effect of substance P in 
nicotine-induced transmissions have been well documented in several 
substance P systems. In addition, nicotine has been used to produce 
cholinergic transmissions in isolated rat atria (Chiang and Leaders, 
1965) and in intact animals such as dogs (Smith et al., 1985) and 
guinea-pig (Leeman et al. , 1981) • 
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sprague-Dawley r�ts of either sex, weighing 300 to 500g, were 
anesthetized with urethane (2-3mg/g). The he�rts were rapidly rerroved 
and placed in a dish containing cold Krebs-Hensleit solution with the 
follo\dng milliioolar COill?OSition: NaCl 145, KCl 5.4, CaC�2.2, NaHCO.S 
11. 9, and glucose 11.0. The solution in the dish was aerated with 95% 
oxygen, 5% carbon dioxide while the atria were dissected free from the 
ventricles and cleared of as nuch tissue as possible. The atria were 
then placed in an organ bath containing Krebs-Hensleit solution which 
w� maintained at 31 CC and gassed by bubbling 95% oxygen , 5% carbon 
. 
dioxide through a fine plastic tube. Fluid in the bath was replaced 
through port at the bottom of the bath from a reservoir. The lower 
section of the right atrium w� attached by means of a J-hook and a 
small metal rod to an aluminum clamp. The upper section was attached 
by means of a J-hook and a thread to a strain transducer. Tension was 
adjusted such that the atria were beating near the peak of the 
length-tension curve. Contractions were recorded with a desk model 
J:>l.'W-4B Physiograph. The preparation was allowed to stablize for a 
period of 0.5-1 hour before any drugs were added to the bath. 
SUbstance P or nicotine were added to bring the bath to the !ollowing 
concentrations: 1 x 10-5 t-1, 2 x 10-5 M, and 4 x 10-5 M. To test the 
effect of nicotine in the presence of substance P, the latter was 
added first and a period of 1 minute was allowed before the addition 
of nicotine. Because nicotine has a prolonged blocking effect on 
nicotinic receptors after its initial stimulating action, a 1-hour 
recovery with repeated washing was interposed between tests with 
nicotine. A 20-m:inute recovery with repeated washing was interposed 
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between tests �'lith substance P. Blocking agents used were abropine 
sulfate { 1. x 10-6 Mh a muscarinic blocker, and hexamathonium 
chloride (i X 10-6. M), a nicotinic blocker. 
Drug preparations: Substance P solution was prepared py 
dissolving 0.50mg of ·the peptide in 9.25 rn1 of distilled water. TWo 
drops of glacial acetic acid were then added to acidify the solution. 
This was necessa� for storage pur;poses because the peptide's 
biological activity is known to be maintained at about pH 4. Nicotine 
sol�tion was prepared py diluting a'preparation containing 100% of· the 
alkaloid in distilled water to achieve the desired concentrations. 
Drugs were added to the bath with a 1 ml-syringe 
Exper irnental control: Blank control sarrples were prepared py 
adding 2 drops of glacial ace�ic acid .to the same amount of distilled 
water used in the preparation of substance P. Control solutions were 
added to the bath as described.above. 
Below are step-by-atep procedures that were followed during 
drug administration: 
(1) The heart was allowed to beat constantly for 30 mins .  
(2) Nicotine (1 x. 10-5 N) was then added into the bath to activate 
nicotinic receptors which will in turn produce cholinergic 
transmission in postganglionic parasympathetic neurons. 
( 3) The system was allowed to run for 3 mi.ns. with continuous 
recording of contractions 
(4) The bath was then flushed 4 times with Krebs-Hensleit solution to 
reroove nicotine conpletely (one flush eve� 15 mi.ns.: total tine= 60 
mins.) 
{5) The contractions were then allowed to return to baseline. 
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(6) Substance P (1 x 10-5 Z.l) was added to the bath; the system was 
allowed to run for 1 min. with continuous r.ecor.ding of cont�actions. 
(7) Nicotine was then added into the bath (same cone. as in step 2) 
(8) The system was allowed to run for 3 mins. with continuous 
reco�ding of contractions. 
19) The bath was flushed as described in step 4 
(10) The contractions were then allowed to return to baseline and 
steps 2, 3, and 4 were repeated. 
(11) The entire procedure was repeated using different concentrations 
of nicotine and substance P. 
(13) For the effect of substance P alone, steps 1, 6, 3, and 9 were 
repeated in that ·Order. 
(14) Step 13 was then repeated using different concentrations of 
substance P. 
Atrial rate and force of contraction were determined as 
follows: '!he heights of contractions produced by the atria as recorded 
\'lere measured in centimeters with the aid of a ruler and a pair of 
dividers. If the contractions were all uniform, the height of a single 
contraction was measured. In situations where contraction heights 
varied, an average height was obtained from all contractions produced. 
The height of contraction obtained during the 10 second period before 
drug addition was taken to be the control. After drug addition, the 
system was allowed to run for 3 minutes with continuous recording of 
contractions. The contractions which represented the maxim.un drug 
effect were then measured as described above. At the erii of each 
experiment, the atria were renoved from the organ bath and a one gram 
weight was hung from the transducer.The tension produced by the weight 
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was recorded and then measured in centimeters. This served to 
calibrate the strain gauge in terms of grams of tension per centimeter 
of � deflection. For statistical analyses, the heights of 
contractions obtained before. and after drug addition were expressed as 
develq>ed tensions (grams) by using the relationsHip obtained from the 
height produced by one gram of tension. 
Statist:ical analyses were done according to methods described by 
Scheffler ( 1969). 
MATERIALS: SUbstance P and nicotine were purchase8 from Sigma Chemical 
Corrpany; st. Louis, MO.; atropine sulfate and hexamatbonhun chloride 
were purchased frOm NUtritional Biochemical Corporation. ; Cleveland, 
Cllio. Desk m:x:lei Dl>n?-4B Physiograph ana Strain transducer are products 
of Narco Bio-systems; Houston, Tex�. A diagrammatic representation of 
the experimental set up is shown in figure 9 
RESULTS 
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Atrial r�spons�s to nicotine: The usual blphaslc response to 
nicotine �as observed at elI concentrations tested. The Initial 
decrease In contractile force was observed Immediately after the 
addition of the drug }o the bath (about 5 beats after the addition of 
nicotine). The average time to maximum Inhibition was about 2 seconds. 
The Inhibitory effect lasted about 4 seconds and was Immediately 
foiJowed by a positive l�otroplc response that was maintained for 
several minutes. Figure 7 shows typical atrial responses to nicotine 
(1.07+ 0.098, 0.98±0.058, 0.85.:t0.074 for 1 X 10-5 M, 2 X 10-5 M �nd 4 X 
10-5 M respectively). The negatJve Inotropic response to nlcotJne was 
significant at all concentrations tested (p < .05) except for 1 X 10-5 
M. Atrial dose/response curve to nicotine is shown in figure 5. 
Chrcnotroplc response to nicotine was insignificant at all 
concentration tested. 
Atrial response to substan�e P; Substance P had an lnlbltory 
effect on atrial contractil tty. The negative Inotropic response to 
substance P (0.95±0.089, 0.84±0.094� 0.74±0.69 for 1 � 10-5, 2 X 10-5, 
and 4 X 10-5 respectively) was significant at all concentrations 
tested (P < .05 for 1 X 10-5 M, P < .01 for 2 X 10-5 M and for 4 X 
10-5 M) and occurred within a few beats from the addition of the drug 
to the bath. The maximal Inhibitory response was achieved 5 to 10 
seconds after drug addition and was maintained for several minutes 
before recovery. The period of recovery varied depending on the 
strength of atrial contraction and drug dosage used. For example, 
atria that produced a strong contractile force recovered faster than 
those that produced a weak contractile force before drug addition. At 
a gtven force of contraction, the htgher the drug dosage the longer 
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recovery. The period of reco.very varied depending on the strength of 
atrial contraction and drug dosage used. For example, atria that 
produced a strong contractile force recovered faster than those that 
produced a weak contractile force before drug addition. At a given 
force of contraction, the higher the drug dosage the longer the period 
of recovery. For example, the recovery period for; atria exposed to 1 X 
10-5 l1 of substance P doubled when the same atria were subjected to 2 
X 10-5 M of the peptide. Increasing the concentration of substance P 
to 4 X 10-5 f-1 did not triple the period of recovery. However, the 
periqd of recovery was longer than that obtained with 2 X 10-s· r-1. The 
degree of inhibition was directly proportional to drug dosage for the 
3 concentrations tested. At 4 X 10-5 M, complete �nhibition of 
contr�ctions· were recorded for oost atria. Thus, no concentrq.tions 
higher than 4 X 10-5 M were tested. Concentrations of substance P less 
than 1 X 10-5 M had no effect on atrial contractility. Figure 8 shows 
typical at"rial responses to the 3 concentrations of 'Substance P 
tested. Neither atropine 'Sulfate (1 X 10-6 M), a nuscarinic blocker, 
nor hexarnathoni� chloride (1 X,l0-6 M), a nicotinic blocker were able 
to abolish the inhibitory effects of substance P. Figure 4 shows the 
atrial dose/response curve to substance P. Chronotropic responses of 
atria to substance P were not significant at any concentration tested 
(P > .OS). Table 2 shows average atrial chronotropic responses 
expressed in beats per minute before and after substance P addition. 
(average beats per minute obtained from 3 concentrations of substance 
P tested are 256± 12. 1, 284+ 10.4, 270±: 14. 6 for 1 X 10-5 M, 2 X 10-5 
M, 4 X 10-5M re�tively) . 
Blank control: Five blank controls were used in order to 
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determine whether the acidified medium in Which substance P was 
dissolved had i tselr any atrial effects. The blanks were prepared in 
the same manner as the substance P preparation, with the exception of 
the addition of substance P. These blanks preparations produced no 
discernable change in either rate or force of contraction. 
Atrial responses to nicotine in the presence of substance P: 
No positive inotropic response to nicotine was observed in the 
presence of substance P for any concentration of nicotine and 
substance P tested. It is difficult to tell Whether the negative 
corrponent of nicotinic response occured or not 'Since substance P has 
irnnediate inhibitory effect on atrial contractility. Howevet, ·it 
appeared that there was more inhibition when nicotine and substance P 
are corrbined than eithe,r alone. For exarrple, the mean { S.E. ) 
inotropic response to substance P { 4 X 10-5 l-1) alone was 0. 7 4±:0. 069 
conpared to 0.64±. 0. 060 obtained when nicotine {4 X 10-5 N) was added 
to fhe bath in the presence· of substance P (4 X 10-5 M); a difference 
of . - 0.10. The response to nicotine (4 X 10-5) alone was 0.85 0.063. 
This pattern was observed for the 3 concentrations of nicotine and 
substance P tested. This may i.nply that nicotine has an additive 
effect in the presence of substance P. Figures 1 to 3 sh0\'1 inotropic 
responses to nicotine, substance P, nicotine in the presence of 
substance P, and response to nicotine follow�ng recovery from 
substance P. The negative inotropic responses prcx:luced by nicotine 
after the conplete rem:>val of substance P and nicotine from the bath 
were identical to those that were initially prcx:luced at the start· of 
each experinent. 
NIC. 1 � 10'"6f.1 
Before After 
' Exp. NO. g g ---- -------
1 2.16 2. 09. 
2 0.89. 0.75 
3 l.OQ 0.96 
4 1. 40 1.35, 
5 0.75 0. 61 
6 1. 12' 0. 91 
7 1.67 1.60 
8 0.87 0. 72 
9 0.96, 0.83 
10 2.29 2.0?, 
11 0.79 ._ 0.57 
12 1.11 0.87 
13 1.60 1. 43 
14 1.33' 1.25 
15 1.04 0.96 
16 0.88 0.79 
17 1.31 1.13 
18 1. 01 0.81 
19 1.25 0.96' 
20 0.92 0.67 
�mAN 1.22 1.07 
S.D. 0.43 0.44 
S.E. 0.096 0.098 
t 1.091 
p > 0.05 
SP. 1 X 10-,.M 
Before 'After 
g g ---------
2.16 1. 89 
0.89 0.57 
1.00 0.91 
1.40 1.31 
0.75 0.52 
1. 12 0. 92 
1. 67 1.33 
0.87 0.56 
0.96 0. 77 
2.29 1. 76 
0.79 0. 53 
1.11 0.75 
1.60 1.27 
1.33 1.09 
1.04 0. 95 
0.88 0.63 
1.31 1.05 
1.01 0.67 
1.25 0.89 
0.92 0.57 
1.22 0.95 
0.43 0.40 
0.096 0.089 
2.058 
p < 0.05 
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SP+NIC. 1 X 10.,;-M NIC. (Recovery) 'Before After Before After 
g g g g -----t 
2.16 1.87 2.16 2. 09 
0.89 0.55 ' 0.89 0.75 
1.00 0.87 1.00 0.96 
1.40 1.16 1.40 1.35 
0.75 0. 56 0.75 0.61 
1. 12 0.77 1.12 0.97 
1.67 1.21 1.67 1.60 
0.87 0.52 0.87 0.72 
0.96 0.67 0.96 0.83 
2.29 1.67 2.29 2.07 
0.79 0.48 0.79 0. 57 
1.11 0.6l 1. 11 0.87 
1. 60 1.00 1. 60 1.43 
1.33 0.92 1.33 1.25 
1.04 0.75 1-.04 0.96 
0.88 0.51 0.88 0.79 
1.31 0.92 1.31 . 1.13 
1.01 0. 57 1.01 0.81 
1.25 0.49 1.25 0.96 
0.92 0. 76 0.92 0.67 
1.22 0.84 1.22 1.07 
0.43 0.39 0.43 0.44 
0.096 0.087 0.096 0.098 
2. 930 1. 091 
p < 0.01 P > o.65 
Table lA. !<lean tts. E. ) Inotropic responses to nicotine (l\llC) , substance P {SJ;) , 
nicotine in the presence of substance P (SP+NIC) , and nicotine recovery {NIC 
recovery). 191 stands for contractility expressed in gram of tension. 'Before' 
and 1 After 1 represent before and after drug addition respectively. Nurrbers on 
top of table indicate dose of substance P or nicotine tested. 
NIC. 2 X 10"'"1-1 
Before After 
Exp. 00": g g ---- --------
1 1.07 0.83 
2 2.13 1.53 
3 1.33 D.96 
4 1.09 0.86 
5 ·0.87 0.75 
6 1. 67 1.33 
7 1.12 0.83 
8 1.07 0.81 
9 1. 25 1. 20 
10 1.00 0.93 
11 0.84 0.76 
12 2.00 1. 40 
13 1.08 0.91 
14 1.87 1.43 
15 0.89 0.67 
16 1.17 1.04 
17 1.33 1.00 
18 1.07 0.80 
19 0.96 0.83 
20 1. 12 0.79 
SP. 2 X Hf1-i 
Before After 
g g 
1.07 0.27 
2.13 1.36 
1.33 0.68 
1.09 0.73 
0.87 0.51 
1. 67 1.57 
1.12 0.63 
1.07 0.59 
1.25 1.03 
1.00 0.85 
0.84 0.65 
2.00 1.80 
1.08 0.79 
1.87 1.44 
0.89 0.65 
1. 17 0.91 
1. 33 1.00 
1. 07 0.72 
0.96 0.61 
1.12 0.60 
-----�-----
l·mAN 1.24 0.98 1. 24 0.84 
S.D. 0.38 0.26 0.38 0.42 
S. E. 0.085 0.058 0.085 0.094 
t 2.517 3.161 
p < 0.02 p < 0.01 
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SP+NIC. 2 X 10-� NIC. (Recovery) 
Before After Before After 
g g g g 
- ----
1.07 0.25 1.07 0.83 
2.13 1.33 2.13 1. 53 
1.33 0.56 1.33 0. 96 
1.09 0.67 1.09 0.86 
0.87 0.47 0.87 0.75 
1.67 1.40 1.67 1.33 
1.12 0.53 1.12 0.83 
1.07 0.69 1.07 0.87 
1.25 0.89 1.25 1.20 
1.00 0.79 1.00 0.93 
0.84 0.52 0.84 0.76 
2.00 1.37 2.00 1.40 
1.08 0.75 1.08 0.91 
1.87 1.31 1.87 1.43 
0.87 0.60 0.89 0.67 
1.17 0.81 1.17 1.04 
1. 33 0.92 1.33 1.00 
1. 07 0. 65 1.07 0.80 
0. 96 0.59 0.96 0.83 
1.12 0. 43 1.12 0.79 
1.24 0. 78 1. 24 0.78 
0.38 0.34 0.38 0.26 
0.085 0.076 0.085 0.058 
4.037 2. 517 
p < 0.001 p < 0.02 
Table lB. Mean (±s :E.) Inotropic responses to nicotine (NIC) , substance P (SP) , 
nicotine in th� presence of substance P (SP+NIC) , and nicotJne recpvery (NIC) • 
'g' stands for contFactility expres,sed in _gram of tensio11. 'Before' and 'After' 
represent before and after drug addition respectively. ��s on top of table 
indicate dose of substance P or nicotine tested. 
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NIC. 4 X lo-EM SP. 4 X 10-i-1 SP+NIC. 4 X 10S,.1 NIC. (Recovery) 
Before After Before After Before After Before After 
Exp. ro. g g g g g g g g 
---- ------- -----
1 1.07 0.83 1.07 0.69 1. 07 0. 65 1.07 0.83 
2 0.80 0.51 0.80 0.36 0.80 0.40 0.80 0.51 
3 1.08 0.65 1.08 0.57 1.08 0.53 1.08 0.65 
4 1. 33 0.96 1.33 0. 75 1.33 0.68 1.33 0.96 
5 1.13 0.93 1.13 0.89 1.13 0. 79 1.13 0. 93 
6 0.87 0.65 0.87 0.60 0.87 0.56 0.87 0.65 
7 1.33 1.19 1.33 1.03 1. 33 0.92 1.33 1.19 
8 1.09 0.83 1.09 0.73 1.09 0.75 1.09 0.83 
9 1.76 1.09 1.76 1.33 1.76 1.13 1. 76 1.09 
10 0. 89 0.67 0.89 0.60 0.89 0.52 0.89 0.67 
11 0.81 0.76 0.81 0.71 0.81 0.57 0.81 0.76 
12 1.00 0.81 1.00 0.68 1.00 0.73 1.00 0.81 
13 0.69 0.61 0.69 0.53 0. 69 0.53 0.69 0.61 
14 0. 77 0.51 0. 77 0.39 0.77 0.39 0.77 0.51 
15 1.35 1.21 1.35 1.19 1.35 0.93 1.35 1.21 
16 0.87 0.75 0.87 0.64 0. 87 0. 43 0.87 0.75 
17 0.76 0.61 0.76 0. 37 0. 76 0. 29 0. 76 0.61 
18 1.33 1.09 1.33 1.00 1. 33 0.75 1. 33 1.09 
19 1.90 1.61 1.90 1.40 1.90 1.39 1.90 1.61 
20 0.83 0.63 0.83 0.43 0.83 0.49 0.83 0. 63 
-- -- ------------
MEAN 1.08 0.85 1.08 0.74 1.08 0.64 1.08 0.85 
S.D. 0.33 0.28 0.33 0.31 0.33 0.27 0.33 0.28 
S. E. 0.074 0.063 0.074 0.069 0.074 0.060 0.074 0.063 
t 2.464 3.361 4.303 2.464 
p < 0.02 p < 0.01 p < 0.001 p < 0.02 
Table· lC. �lean (±s. E.) Inotropic responses to nicotine (NIC) . substance P (SP) , 
nicotine in the presence of substance P (SP+NIC) , and nicotine recovery (NIC 
recovery). 'g' stands for contractility expressed in gram of tension. 'Before' 
and 'After' represent before and after drug addition respectively. Numbers on 
top of table indicate dose of substance P or nicotine tested 
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1 X 10-5M 2 X 10-l.l 4 X 10--lt 
Exp. No. Before Mter �fore Mter Before Mter 
--- --- ---- --- ----
l. 330 198 150 144 174 150 
2 240 156 201 200 189 162 
3 201 186 305 298 295 283 
4 300 295 298 295 311 300 
5 280, 264 320 301 320 318 
6 340 300 340 312 294 263 
7 220 198 321 308·· 187 163 
8 340 315 297 286 178 154 
9 208 192 300 287 340 321 
lQ 250 231 312 303 360 342 
11 330 298 345 325 312 301 
12 320 318 299 267 328 319 
13 298 267 313 300 299. 290 
14 323 298 277 267� 262 247 
15 350 329 298 287 350 321 
16 206 198 370 359 307 298 
17 275 �44 �90 272 359 � 307 
18 320 300 320 318 287 261 
19 264 230 314 301 314· 300 
20 310 309 262 242 316 304 
MEAN 285 256 297 284 287 270 
S. D. 49.5 53.9 48.4 46. 3  58.4 62.6 
S. E. 11.1 12.1 10.8 10.4 13.1 14.6 
t 1.773 0.868 0.922 
p > 0.05 p > 0.05 p > 0.05 
Table 2. Mean (±sE) Chronotropic responses tQ suDstance P. 'Before' and 'Mter' 
represent before SP addition and after SP addition respectively. Heart rates are 
expressed in beats/mins. Nwrbers on top of the table indicate dose of SP tested. 
Exp. ·NO. 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
l·iFAN 
S.D. 
S. E 
NICOI'INE 
1 X lCfsM 2 X 10--li 
% 
3. 1 
16.4 
4.0 
3.8 
17.9 
13.1 
4.0 
16.9 
13.9 
12.9 
27.1 
21.7 
10.8 
6.0 
7.7 
10. 6  
13. 3  
19.7 
23. 4  
27.5 
13.69 
7.65 
1.710 
· '  
%' 
' ' 
. . 
22.5 
28.1 
28.0 
20.7 
13.8 
20.0 
26.2 
15.3 
4.3 
6.7 
9.5 
30.0 
16.0 
23. 6 
25.4 
11.4 
25.0 
25.0 
13.9 
29.8 
19.76 
7.89 
1.760 
4 X 10-M 
�EP 
1 X l(f M 2 X 1CJ-11 
% % % 
22.5 12.3 75.0 
36. 7 35. 8 36.3 
39.5 9.3 49.0 
28.0 6. 7 32.9 
17.6 30.4 41.5 
24.4 17.9 5. 6 
11.0 20.0 44.0 
24.4 35. 4 18. 1 
37.9 19.4 18. 1 
25.4 25.8 14.7 
6.6 32.2 22.2 
18.7 32. 5 10.0 
11.5 20.8 27.2 
34.5 18.0 22.9 
9. 9 9.0 26.9 
13.8 28. 8 22.7 
19.3 19.4 25. 0 
18.0 34. 2 32.5 
14.8 28.7 36.1 
24.2 37. 7 46.4 
--------
21. 95 23. 72 30.36 
9.69 9.75 15.88 
2. 170 2.200 3. 600 
Table 3. z.Iean (±s. E.) Inotropic responses to nicotine and substance P. 
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4 X lCf� 
% 
35.0 
38.3 
46.9 
44.0 
21.2 
30.8 
23.0 
32.9 
24.2 
32.8 
13.1 
32.0 
23.1 
50.0 
11.9 
26. 2 
50.9 
25.0 
26.1 
40.3 
----
31.4 
II.22 
2.500 
(% 
represents percent decrease in contractility). NUmbers on top of table indicate 
dose of substance P and nicotine tested. 
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Figures 1 to 3. ftlean (±S.E.) Inotropic responses to nicotine (NIC) 1 substance P 
(SP) 1 nicotine in th� presence of substance P (SP+NIC) 1 and nicotine recovery 
(NIC recovery) • q>en and shaded bars represent "before and after" drug cKidition 
respectively. Numbers under each set of bars indicate dose of substance P or 
nicotine tested. Extension bars represent SEl-l 
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Fig 4. �an (t.S.E.) Atrial co�tractile responses to nicotine and sub3tance P 
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Figure 5. TY,pical contractile responses of isolated rat atria to nicotine. 
Arrows indicate piont of addition of drug to the bath. runt>ers below arrow 
indicate concentrations tested. Vertical bar at bottom of the page represents 1 
gram of tension; horizontal bar = 1 s econd. 
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Figure 6. Typical contractile re�nses of isolated rat atria to substance P. 
Arrows indicate piont' of addition of drug to the bath. N.mbers below arrow 
indicate concentrations tested. Vertical bar at bottom of the page represents 1 
gram of tension; horizontal bar = 1 second. 
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I 
Fig 7. A diagrammatic r�rsentation of experimental set up 
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DISCUSSioN 
.ATRIAL RF.SPC!SE TO NICDriNE: The expected biphasic in vitro 
contractile response to nicotine was observed at all concentrations 
tested. A biphasic in vitro contractile response to nicotine has been 
reported for atria from various mammalian species (Lee and Shideman, 
1959; Puri et alr 1968; Leaders and hong, 1962, Loffelholz, 1970. ). 
Priola and �urgeon (1973) demonstrated that in the presence of intact 
cardiac sympathetic nerves, administration of nicotine caused biphasic 
inotropic responses and fhat such positive inotrqpic res.ponses were 
absent in cardiac denervated animals. This finding led to the 
conclusion that the positive conponent of the biphasic res.ponse was 
due to nicotine-induced catecholamine release since extrinsic 
denervation of the heart destroyed postganglionic �thetic neurons. 
Smith and his ccr-Workers reported similar findings from denervated 
canine atria. Several workers have also reported that a large 
proportion of the positive inotropic effects of nicotine results from 
the release of endogenous adrenergic neurotransmitter (Loffelholz, 
1970; Toda and Hayashi, 1982; Burn, 1960; Lee and Shidernan, :1.959). su 
and Bevan (1970) reported that nicotine causes a release of 
norepinephrine from synpathetic nerve endings within the fi'!YOCardium. 
The negative inotropic response has been shown to result from 
acetylcholine released from postganglionic parasympathetic neurons 
when the alkaloid binds to neuron's receptors. (Mjos and Ilebekk, 
1973; Fenton and Dobson, Jr., 1985) • This claim is supported, along 
with the work of other researchers, by results obtained from the study 
of .intrinsic innervation of the canine heart (Priola et al., 1977.). and 
from comparison of in vivo and in vitro cholinergic r�nses of 
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normal and denervated canine heart (Smith et al., 1985). Their methcxle 
include the 'use of dogs that were subjected to total extrinsic cardiac 
denervation because this procedure· elimin�tes postganglionic 
�thetic neurons but not par�athetic postganglionic neurons. 
They sh��ed that activation of the postganglionic parasympathetic 
neurons with nicotine ptoduced negative inotropic effects on the 
heart. Although the terminal mechanism for the response of nicotine or 
acetylcholine is cholinergic activation of muscarinic receptors, it 
was noted that the response to nicotine requires as an intermediate 
step the conduction of nerve impulses since the response to nicotine, 
but not the response to acetylcholine, could be blocked by 
tetrodotoxin. The negative inotropic effect of nicotine can also be 
blocked by hexamathonium chloride (a nicotinic cholinergic blocker) or 
atropine sulfate (a muscarinic cholinergic blocker), whereas the 
respo:nSe to acetylcholine is blocked by atropine only. Their results 
are taken to indicate that nicotine prOduces its initial negative 
inotropy by activating postparasympathetic neur6ns with subsequent 
release of acetylcholine, whereas acetylcholine acts primarily on 
muscarinic receptors oh the effector. 
Smith et al have shown that the positive conponent of 
nicotinic response was absent in animals that were subjected to total 
extrinsic cardiac denervation. Their results are taken to indicate 
that the secondary positive response to nicotine could be due to 
nicotine-induced catecholamine release since extrinsic denervation of 
the heart destroys postganglionic sympathetic neurons and eliminates 
cardiac stores of norepinephrine JPriola et. al ., 1981). Several .. 
workers have shown that nicotine agents cause release of 
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nor�inephrine from adrenergically innervated tissues {Cabrera et a}., 
1966; Loffelholtz, '1970) � It JtJas dezronstr�ted. that nicotipe agents 
induced generation and propagation of ·inpulses along the 
postganglionic .adrenergic nerve fibers {Cabrera et al 1966; Ferry, 
1963; Cabrera and 'I'orrance, 1964) and it was suggested that these 
impulses reaching �renergic nerve te�ls caused release of 
nor�inephrioe {Ferry, 1963). However, attenpts to test this proposal 
by using tetrodotoxin, which selectively blocks neuronal conduction 
have resulted '<>nly in controversy. 
,ATRIAL RF.SPCJ-E  TO SUBSTAN:E P: The evidence for substance P 
as a neuromodulator has been documented in many systems. For exanple, 
the modulatory actions of the �ide was demonstrated in amphibia in 
Wbich substance P modulated the sensitivity of nicotinic receptors 
during cholinergic transmissions {Akusu et al. , 1983). Also, the 
inhibitory influence of substance P on nicotinic-induced responses 
was observed in preparations such as bovine adrenal chromaffin cells 
{Livett et a}., 1979) and in cat Renstlaw cells {Belcher eta}., 1979). 
In the present study, substance P had no modulatory effects on 
nicotine-induced transmissions in intrinsic parasympathetic.neurons in 
isolated rat atria preparations since it neither inhibited nor 
enhanced the negative chronotropic �r inotropic responses to nicotine. 
Combined doses of nicotine and · substance P merely prodUPed an additive 
negative inotropy. Instead, rnicramolar concentrations of the peptide 
(1 X 10-5 to 4 X 10-5 1>1) produced negative inotropic responses that 
could not be abolished by atropine sulfate {1 X 10-6 M) or 
hexamathoniurn chloride {1 X 10-6 M). Substance P had no evident 
chronotropic effects. The precise site and mechanisms of actions of 
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the peptide is not understood� However, it is unlikely that subs�an� 
P mediated its effects via cholinergic re9eptors since the peptide's 
inhibitory actions were not blocked by atropine sulfate (a nuscarinic 
cholinergic blocker} or hexamathonium. chloride ( a nicotinic 
cholinergic blocker} . This may imply that substance P produces a 
direct negative inotropic effect in rat �ocardium. The control blanks 
containing only the medium in which substance P is .normally suspended 
had no effect on atrial contractility. This ruled out the :possibility 
that the suspending medium which is slightly acidified might be the 
iphibiting agent. 
Previoosly, not much had been demonstrated about the cardiac 
action of substance P. The association of substance P w�th sensory 
fibers has been well documented in sorre areas of the central nervous 
system. For exanple, imrunohistochemical ptudies have found subtance P 
to be present in sorre of the small unmyelinated primary sensory 
neurons of the spinal cord and brain stem. In additi9n, stimulation of 
sensory neurons releases substance P from the spi�· cord. Application 
of substance P to neurons in the spinal cord excites neuro� that are 
known to be excited by painful stimuli. Painful stimu�i are knqwn to 
selectively activate unmyelinated sensory fibers. Thus, it is believed 
that substance P may be, an excitatory transmitter released from 
unmyelinated fibers that res:pond to painful stinulation. A similar 
association of the peptide with sensory fibers was reported in the 
guinea pig heart (Papka et al., 1981). Since no investigator has 
previously tested for the cardiac action of substance P, very little 
is ,knqwn about its mechanism of action. The fact that niootine and 
substance P are indeed acting by different mechanisms is clear from 
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the differential blocking.effect of atropine sulfate pr hexamathonium 
chlo;_ide. It is possibl� that the mechanisms of actions of substance P 
are similar to those of agents ·that are known to inhib,it cardiac 
contract;lity. Agents such as verapamil, nifedipine, and diltiazem 
that inhibit calcium influx have direct inhibitory effects on cardiac 
contractility. Cardiac rn.1scle is highly dependent upon calcium influx 
for normal function. Calcium influx blockers bind. to merrbrane 
$tructures responsib�e for the "slow inward cu�rent" - structures 
thousht to be- channels ruch like the sodium chQimels of· nerve but 
relatively selective for calcium. Tissues that require calcium influx 
foF normal activity are therefore susceptible to plock by thes e 
ag�ts. Calcium channel blockade by these drugs reserrbles �odium 
channel blockade by local anesthetics. The drugs act from the inner 
side of the membrane and bind more effective�y to channels in 
d�larized membranes. Impulse generation in the sinoatrial node and 
conduction in the atrioventricular node may be reduced or blocked by 
calcium inhibitors. Excitation-contraction coupling in all cardiac 
cells requires calcium influx, so these agents inhibit cardiac 
contractility in a dose-dependent fashion. Subs�ance P may be 
inhibiting calcium influx, in a· similar manner; in additipn, substance 
P reduced atrial contractions in a dose-dependent manner for the 3 
concentrations tested. Sodium channel-blocking drugs such as quinidine 
or procainamide are known to depress the pacemaker rate, cooouction 
rate, and excitability of cardiac cells. These actions result because 
these drugs are able to block activatec;l sodium channels. It is 
possible that substance P is inhibiting cardiac contractility by 
blocking activated as well as inactivated sodium channels. However, 
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substance P did not change the rate, suggesting that substance P is 
probably not affecting sodium channels. 
ATRIAL RF.SP®E TO NICOl'INE IN THE PRESEOCE CF stJBSl'A.OCE P: 
The secondary positive response to nicotine was not observed in the 
presence of substance P. It was difficult to tell whether the negative 
response to nicotine occured or not in the presence of subtance P 
because the peptide itself had an inhibitory effect on atrial 
contractility. Nevertheless, nicotine seemed to enhance the negative 
inotropic effects of substance P for all concentrations of the peptide 
tes ted. The res ults obtained from these experiments, however, ruled 
out the possibility that nicotine mdght have an additive effect in the 
presence of substance P because the difference between the means were 
! 
insignificant for all concentrations of nicotine and substance P 
tested. The mechanism by which nicotine inhibits atrial contractility 
differs from that of substance P since the inhibitory action of 
nicotine is caused by acetylcholine release from postganglionic 
parasympathetic neurons when the alkaloid binds to the neuron's 
recptors. This action can be abolished by atropine sulfate or 
hexamathonium chloride. Thus, substance P and nicotine can have 
I 
additive effects by acting via different mechanisms. It is possible 
• 
that substance P may inhibit cholinesterase and as such may prolong 
the presence of acetylcholine in the synaptic cleft. But the fact that 
the effect of substance P was not blocked by either hexamathonium 
chloride or atropine sulfate appears to rule out this possibility. The 
administration of cholinesterase inhibitors such as edrophonium, 
physostigmine, orneostigmine. leads to effects on the' heart that mimic 
the effects of vagal nerve activation. Heart rate decreases, 
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conduction velocity through the atrioventricular junction diminishes, 
atrial contractility decreases, and cardiac output falls. However, 
cholinesterase inhibitors are known to prolong the response in time; a 
charateristic that was not observed with substance P. 
SUB.STAN:::E P AND CARDIAC PAIN: Specific inmlnoassays and 
immunohistochemical techniques have been used to study the presence of 
substance P in various neuronal systems. A good example was the 
detection of substance P immunoreactive fibers in the guinea pig heart 
(Reinecke and Forssrnann, 1980) . The functions of these substance 
P-immunoreactive fibers are no� well understood. Same investigators 
suggested that these fibers could be involved in sensory transmissions 
that are associated with cardiac pain (Hokfelt et al, 1980; Ljungdahl 
et al, 1981) whereas others reported that in addition to sensory 
transmission, the peptide is involved in the regulation of coronary 
blood flow (Reinecke et al, 1980) . Because substance 
P-immunoreactivity has been demonstrated in the guinea-pig vagus nerve 
and dorsal root ganglia, it is conceivable that the substance 
P-immunoreactive nerve fibers in the heart are part of an afferent 
sensory system which contributes to the regulation of coronary blood 
flow or is involved in pain perception. It is postulated that 
substance P liberated from pain-associated fibers in the heart might 
have a modifying action on the heart. The functional role, if any, for 
substance P producing a direct negative inotropy during episodes of 
cardic pain has yet to be elucidated. However, such direct negative 
inotropy may be protective py counteracting excitability produced py 
catecholarnines released from adrenals during cardiac pain episodes. 
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